Chuck A J, Murphy J, Weiss J B, Grennan D M
Ann Rheum Dis. 1986 Feb;45(2):162-6. doi: 10.1136/ard.45.2.162.
Urinary glycosaminoglycan (GAG) excretion was measured in 24 patients with active rheumatoid arthritis (RA) before and after treatment with conventional second-line agents. Urinary GAG excretion was also measured in normal controls, patients with osteoarthritis (OA), and patients with acute myocardial infarction (MI). Total GAG excretion was increased in the RA group and fell after second-line therapy (p less than 0.01). More low than high molecular weight GAG was excreted in the active RA group, and this pattern was reversed after treatment. Excretion of total, high and low molecular weight GAG in the OA group did not differ significantly from controls. Total GAG excretion was increased in the MI group when compared with controls (p less than 0.02) and consisted mainly of high molecular weight GAG. The serial measurement of urinary GAG provides a further index of disease activity and may help to monitor response to treatment.
在24例活动性类风湿关节炎（RA）患者接受传统二线药物治疗前后，测量其尿糖胺聚糖（GAG）排泄量。同时也测量了正常对照组、骨关节炎（OA）患者及急性心肌梗死（MI）患者的尿GAG排泄量。RA组总GAG排泄量增加，二线治疗后下降（p<0.01）。活动期RA组排泄的低分子量GAG多于高分子量GAG，治疗后这种模式逆转。OA组总、高和低分子量GAG排泄量与对照组无显著差异。MI组总GAG排泄量与对照组相比增加（p<0.02），且主要由高分子量GAG组成。尿GAG的系列测量提供了疾病活动的进一步指标，并可能有助于监测治疗反应。
